NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$12.00

04 Mar
2026

-0.560

OPEN

$12.36

-4.46%

HIGH

$12.74

849,308

LOW

$12.00

TARGET
$23.867 98.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 23.7 9.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 78.7% - 61.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 133.2 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx23.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx64.6 M
Book Value Per Share xxxxxxxxxxxxxxx267.3
Net Operating Cash Flow xxxxxxxxxxxxxxx125.4 M
Net Profit Margin xxxxxxxxxxxxxxx47.09 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.67 %
Return on Invested Capital xxxxxxxxxxxxxxx8.67 %
Return on Assets xxxxxxxxxxxxxxx8.09 %
Return on Equity xxxxxxxxxxxxxxx8.67 %
Return on Total Capital xxxxxxxxxxxxxxx6.27 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx125.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx296 M
Price To Book Value xxxxxxxxxxxxxxx6.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.06 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx43 M
Research & Development xxxxxxxxxxxxxxx36 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

02/03/2026

1

Buy

$22.00

83.33%

Bell Potter assesses the 2025 result from Neuren Pharmaceuticals has demonstrated it is comfortably profitable based on the existing royalty stream from Daybue that more than offsets R&D expenditure on the second asset, NNZ-2591.

The phase 3 trial for NNZ-2591 in Phelan McDermid syndrome is now recruiting and despite results being 18 months away represents a key inflection opportunity for the company.

Daybue 2025 sales were US$391m, up 12%, and the broker found the bullish 2026 guidance from Acadia of US$460-490m in sales "most interesting" as it implies an acceleration for 2025 that is well above prior forecasts.

Buy rating and $22 target maintained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.10 cents.
Bell Potter forecasts a full year FY27 EPS of 13.10 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

11/02/2026

1

Buy

$23.00

91.67%

Neuren Pharmaceuticals is now in a trading halt pending an announcement regarding FDA feedback on its Pitt Hopkins Syndrome and hypoxic-ischemic encephalopathy programs.

Canaccord Genuity currently does not include value for this program in its assessment of the stock.

The company has had ongoing constructive conversations with the FDA in relation to its program and the broker would be surprised if additional extensive clinical data are mandated.

No change to Buy rating or $23 target.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 61.00 cents.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
FNArena Corporate Results Monitor – 02-03-2026

Mar 02 2026 - Australia
2
Next Week At A Glance – 16-20 Feb 2026

Feb 13 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Feb 12, 2026

Feb 12 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Feb 11, 2026

Feb 11 2026 - Daily Market Reports
5
Rudi’s View: February Favourites & Avoids

Jan 29 2026 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
2
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
3
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
4
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
5
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
6
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
7
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
8
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
9
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
10
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View